A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Subjects With Parkinson`s Disease and Motor Fluctuations

Trial Profile

A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Subjects With Parkinson`s Disease and Motor Fluctuations

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs PF 6649751 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
    • 07 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top